-
-
-
-
-
-
-
Celcuity files sNDA for gedatolisib in PIK3CA mutant breast cancer
-
-
-
-
-
-
-
Celcuity's Revtorpyk added to NCCN breast cancer guidelines
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Celcuity Inc (CELC)
-
-
-
-
-
-
-
Celcuity (CELC) Reiterated at Market Outperform by Citizens Ahead of ASCO Data
-
-
-
-
-
-
-
Celcuity Inc (CELC) PT Raised to $165 at Guggenheim
-
-
-
-
-
-
-
Celcuity Inc (CELC) PT Raised to $125 at Stifel on Reduced OpEx Estimates
-
-
-
-
-
-
-
Jefferies lists 5 biotech M&A candidates for 2026
-
482,493 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


